1242088-46-5

Basic information

• Product Name: C₃₈H₄₄N₈O₆
• Synonyms: C₃₈H₄₄N₈O₆
• CAS NO: 1242088-46-5
• Molecular Weight: 708.817
• Mol File: 1242088-46-5.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: C₃₈H₄₄N₈O₆(CAS DataBase Reference)
• NIST Chemistry Reference: C₃₈H₄₄N₈O₆(1242088-46-5)
• EPA Substance Registry System: C₃₈H₄₄N₈O₆(1242088-46-5)

Safety Data

• Hazardous Substances Data: 1242088-46-5(Hazardous Substances Data)

Upstream product

• 1242094-27-4 C₂₀H₂₅IN₄O₃ 
• 1242088-45-4 C₃₈H₄₅N₇O₅ 
• 59190-99-7 (2S)-2-(methoxycarbonylamino)propanoic acid 
• 1242094-28-5 C₁₈H₂₂INO₅ 
• 1242094-29-6 tert-butyl (S)-2-[5-(4-iodophenyl)-1H-imidazol-2-yl]pyrrolidine-1-carboxylate 
• 1208008-43-8 C₂₁H₂₉N₃O₂Si 
• 1208008-44-9 (S)-2-(5-ethynyl-1H-benzoimidazol-2-yl)-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 111398-44-8 N-methoxycarbonyl-L-valine 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 1208007-67-3 1,1-dimethylethyl (2S)-2-(5-bromo-1H-benzimidazol-2-yl)-1-pyrrolidinecarboxylate 

Relevant articles and documents

NOVEL BENZIMIDAZOLE DERIVATIVES

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.